middle.news
EVE Health Secures Nextract, Advances Into $16B Pharma Markets with New Products
9:47am on Thursday 31st of July, 2025 AEST
•
Healthcare
Read Story
EVE Health Secures Nextract, Advances Into $16B Pharma Markets with New Products
9:47am on Thursday 31st of July, 2025 AEST
Key Points
Acquisition of Nextract completed, securing solubility delivery IP
Raised $1 million via placement and share purchase plan
Entered high-growth markets with Libbo and Dyspro products
First commercial order for Dyspro submitted, manufacturing underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Eve Health (ASX:EVE)
OPEN ARTICLE